Ocular Therapeutix's AXPAXLI Achieves Phase 3 Success, NDA Planned; Q1 Revenue $10.8M, $667M Cash
OCUL sits 54% above its 52-week low of $6.23.
Summary
Ocular Therapeutix reported positive Phase 3 SOL-1 results for its lead candidate AXPAXLI in wet AMD, meeting the primary endpoint and demonstrating superiority. The company plans to submit a New Drug Application (NDA) based on this data, which is a significant de-risking event and potential value driver for the biotech. Concurrently, Ocular Therapeutix announced Q1 2026 results, reporting $10.8 million in revenue and an $88.6 million net loss. Critically, the company maintains a strong cash position of $666.7 million as of March 31, 2026, which is expected to fund operations into 2028, providing a substantial runway for continued development. This financial stability, coupled with the clinical success, positions the company favorably. Investors will now watch for further FDA discussions and the formal NDA submission for AXPAXLI, as well as upcoming readouts from the SOL-R and HELIOS-3 trials.
At the time of this announcement, OCUL was trading at $9.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $6.23 to $16.44. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.